LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
Antonio Passaro, Byoung Chul Cho, Yan Wang et al. · Annals of Oncology · 2023
Cited by 17 works. doi:10.1016/j.annonc.2023.10.063 Open-access PDF
Authors
- Antonio Passaro
- Byoung Chul Cho
- Yan Wang
- Barbara L. Melosky
- Raffaele Califano
- Soo Hoon Lee
- Nicolas Girard
- Karen L. Reckamp
- Toshiaki Takahashi
- Enriqueta Felip
- Ryan D. Gentzler
- Sanjay Popat
- William N. William
- Tao Sun
- Shalin Jyotindra Shah
- B. Diorio
- Roland Elmar Knoblauch
- Joshua Michael Bauml
- M.R. García-Campelo
- Jing Wang